Use of Blemaren citrate formula in gout patients with nephrolithiasis

Abstract

Objective - to evaluate the effect of Blemaren on uric acid (UA) metabolic parameters in gout patients with nephrolithiasis and the possibilities of its use in combined therapy for gout.
Patients and methods. The study included 30 patients (26 males and 4 females) aged 50 years (range 36 to 61 years) who had crystal-verified gout in the presence of nephrolithiasis. All the patients took Blemaren in an initial dose of 3 g/day; the dose of the drug was adjusted depending on the urine acidity (the pH value was maintained at 6,2-6,8). Physical and laboratory studies were conducted before and a month after the drug's administration. The treatment performed before the patients ' inclusion into the study remained the same for at least 2 months. Fifteen patients received allopurinol in a dose of 100-200 mg/day.
Results. After completion of a course of Blemaren therapy, there was an 8% reduction in the mean serum UA levels, which correlated with an increase in its daily excretion (by an average of 20%). The highest increase in UA excretion was observed in 20 patients with baseline hypoex-cretion (<700 mg/day): from 226,3 (range 201,6-436,8) to 635,0 (range 272,2-705,6) mg/day (p = 0,01). UA excretion substantially unchanged in patients with normal uricosuria (>700 mg/day). Side effects that could cause the agent to be discontinued were absent. Conclusion. The Blemaren citrate formula used in gout patients with nephrolithiasis causes a significant increase in the renal excretion of UA (p = 0,01), normalizes its metabolic parameters, and shows a high safety, without worsening hepatic and renal functions and electrolyte metabolism.